Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia

Cancer is a clonal evolutionary process, caused by successive accumulation of genetic alterations providing milestones of tumor initiation, progression, dissemination, and/or resistance to certain therapeutic regimes. To unravel these milestones we propose a framework, tumor evolutionary directed graphs (TEDG), which is able to characterize the history of genetic alterations by integrating longitudinal and cross-sectional genomic data. We applied TEDG to a chronic lymphocytic leukemia (CLL) cohort of 70 patients spanning 12 years and show that: (a) the evolution of CLL follows a time-ordered process represented as a global flow in TEDG that proceeds from initiating events to late events; (b) there are two distinct and mutually exclusive evolutionary paths of CLL evolution; (c) higher fitness clones are present in later stages of the disease, indicating a progressive clonal replacement with more aggressive clones. Our results suggest that TEDG may constitute an effective framework to recapitulate the evolutionary history of tumors. DOI: http://dx.doi.org/10.7554/eLife.02869.001

[1]  James R. Downing,et al.  Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2010, Nature.

[2]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[3]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[4]  A. Ashworth,et al.  Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. , 2012, Blood.

[5]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[6]  C. Yau,et al.  Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia , 2012, Leukemia.

[7]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[8]  A. Tsimberidou,et al.  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .

[9]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[10]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[11]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[12]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[13]  Camille Stephan-Otto Attolini,et al.  A mathematical framework to determine the temporal sequence of somatic genetic events in cancer , 2010, Proceedings of the National Academy of Sciences.

[14]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.

[15]  J. Gribben,et al.  Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.

[16]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[17]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[18]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[19]  D. Rossi,et al.  The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors , 2009, British journal of haematology.

[20]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[21]  B. Parsons Monoclonal tumor origin is an underlying misconception of the RESIC approach , 2011, Proceedings of the National Academy of Sciences.

[22]  Michael Hallek,et al.  Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. , 2009, Blood.

[23]  Raul Rabadan,et al.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.

[24]  L. Medeiros,et al.  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .

[25]  Y. Pekarsky,et al.  NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.

[26]  Raul Rabadan,et al.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.

[27]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[28]  Stavroula Ntoufa,et al.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients , 2011, Haematologica.

[29]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[30]  S. Richards,et al.  Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. , 2008, The New England journal of medicine.

[31]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[32]  A. Ashworth,et al.  Whole genome sequencing of matched primary and metastatic acral melanomas. , 2012, Genome research.

[33]  Marcos González,et al.  Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. , 2009, Blood.

[34]  C. Nordling A New Theory on the Cancer-inducing Mechanism , 1953, British Journal of Cancer.

[35]  P. Ouillette,et al.  Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia , 2012, Genes, chromosomes & cancer.

[36]  J. Byrd,et al.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study , 2012, Leukemia & lymphoma.

[37]  T. Haferlach,et al.  Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL , 2012, British journal of haematology.

[38]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[39]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Pecciarini,et al.  General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. , 2011, Blood.

[41]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[42]  D. Rossi,et al.  The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.

[43]  J. Salk Clonal evolution in cancer , 2010 .

[44]  Š. Pospíšilová,et al.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.

[45]  Muriel Médard,et al.  Network deconvolution as a general method to distinguish direct dependencies in networks , 2013, Nature Biotechnology.

[46]  Luca Laurenti,et al.  NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL , 2012, Haematologica.

[47]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[48]  Andrea Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[49]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[50]  R. Dalla‐Favera,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[51]  G. Morgan,et al.  Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[53]  M. Dyer,et al.  Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Catovsky,et al.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.

[55]  M. Stratton,et al.  A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.